Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M17.3Revenue (TTM) $M10.9Net Margin (%)24.7Altman Z-Score-34.0
Enterprise Value $M16.3EPS (TTM) $0.9Operating Margin %25.5Piotroski F-Score5
P/E(ttm)10.0Beneish M-Score--Pre-tax Margin (%)24.7Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.4Cash flow > EarningsN
Price/Sales2.05-y EBITDA Growth Rate %-23.7Current Ratio0.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)166Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M2.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OPNT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

OPNT is held by these investors:



OPNT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sinclair MichaelExecutive Chairman, 10% Owner 2017-01-17Buy3,500$7.0121.26view
CRYSTAL ROGERCEO, 10% Owner 2017-01-17Buy3,475$6.9921.6view
Pollack KevinSee Remarks 2017-01-13Buy4,820$6.9821.78view
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.5142.86view
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.5142.86view
COHEN MARC AChairman,CEO,Treas, & Sec, 10% Owner 2012-06-14Sell243$2450-99.65view
KAISER RONALD WDirector 2012-06-06Sell100$2604-99.67view
KAISER RONALD WDirector 2010-12-08Sell100$2608-99.67view
Wesley Melvin IIICFO 2010-11-29Sell11$2424-99.65view
Wesley Melvin IIICFO 2010-11-18Sell23$2190-99.61view

Quarterly/Annual Reports about OPNT:

News about OPNT:

Articles On GuruFocus.com
ANGEL Program Gets National Attention Feb 13 2017 

More From Other Websites
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 06 2017
Opiant Pharmaceuticals, Inc. Announces the Appointment of Dr. Phil Skolnick as Chief Scientific... Feb 06 2017
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Jan 31 2017
Opiant Pharmaceuticals, Inc. Announces Establishment of Audit, Compensation and Nominating and... Jan 31 2017
Opiant Pharmaceuticals, Inc. Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI)... Jan 26 2017
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 18 2017
Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals Jan 11 2017
[$$] Spare5 Rebrands As Mighty AI, Raises $14 Million Jan 10 2017
Opiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN® Nasal Spray and Heroin Vaccine... Jan 09 2017
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Jan 06 2017
OPIANT PHARMACEUTICALS, INC. Financials Dec 21 2016
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2017 By the Numbers : December 20,... Dec 20 2016
OPNT: Receives $13.7M From Monetizing NARCAN® Nasal Spray Royalties Dec 19 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 19 2016
Opiant Pharmaceuticals, Inc., Reports Fiscal First Quarter 2017 Financial Results and Provides... Dec 16 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Dec 15 2016
Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization Dec 15 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Nov 22 2016
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: 2016 By the Numbers : November 22, 2016 Nov 22 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Nov 10 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)